Loading...
Loading...
EQ| Name | Value |
|---|---|
| Revenues | 4,392.0K |
| Cost of Revenue | 35.0K |
| Gross Profit | 4,357.0K |
| Operating Expense | 9,090.0K |
| Operating I/L | -4,698.0K |
| Other Income/Expense | -735.0K |
| Interest Income | 239.0K |
| Pretax | -5,433.0K |
| Income Tax Expense | 361.0K |
| Net Income/Loss | -5,794.0K |
Equillium, Inc. is a clinical-stage biotechnology company specializing in the development and sale of products for severe autoimmune and immuno-inflammatory disorders. Its lead product candidate, itolizumab (EQ001), is a monoclonal antibody targeting the immune checkpoint receptor CD6. It is currently in Phase III clinical trials for acute graft-versus-host disease and has completed Phase Ib trials for asthma and lupus nephritis. The company also develops EQ101 for cutaneous T cell lymphoma and alopecia areata, and EQ102 for various gastrointestinal diseases.
